Therefore, HMGA2 has been shown to increase drug resistance in a variety of malignant tumors, including nasopharyngeal carcinoma, thereby affecting the therapeutic effect of tumors, and these research results provide new ideas and targets for anti-drug resistance to malignant tumors. This evidence concerns the gene HMGA2 and cancer.